Exemasin is anti cancer drug indicated for the treatment of advanced breast cancer (ABC) in women with natural or induced postmenopausal status whose disease has progressed following anti estrogen therapy alone.
Exemasin is also indicated for the treatment of postmenopausal women with ABC whose disease has progressed following multiple hormonal therapies.
Exemasin is indicated for the adjuvant treatment of postmenopausal women with estrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy
